About The Event

Join us for an update on the Darovasertib Phase 2 interim clinical results and the FDA Type C meeting for the registrational trial design supporting potential accelerated approval in first-line Metastatic Uveal Melanoma (MUM).

Agenda Topics

• Welcome and Introduction
• FDA Guidance Provides Path to Accelerated Approval in First-Line HLA-A2 Negative MUM
• Darovasertib Clinical Data Update in Metastatic Uveal Melanoma
• Darovasertib Clinical Data Update in Neoadjuvant Uveal Melanoma
• Compassionate Use Case Study in Neoadjuvant Uveal Melanoma
• Closing Remarks
• Analyst Q&A

Key Opinion Leader Presenters

• Dr. Meredith McKean, M.D., MPH​, Director, Melanoma and Skin Cancer Research at Sarah Cannon Research Institute
• Prof. Anthony Joshua, MBBS Ph.D. FRACP, Head of the Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent’s Hospital/Garvan Medical Research Institute, Sydney, Australia
• Prof. Mark Shackleton, MBBS, Ph.D., FRACP, Professor of Oncology, Monash University, Director of Oncology, Alfred Health,  Chair, Melanoma and Skin Cancer Trials, Melbourne, Australia

The event will conclude with closing remarks, followed by a live analyst Q&A session

CONTACT US

Investor Inquiries: investor@ideayabio.com